MD FASN - Vertex Pharmaceuticals Pres CEO

All Insiders Germany . 
Stock . Vertex Pharmaceuticals Incorporated . Stakeholders . Insider . MD FASN
VX1 Stock  EUR 470.50  0.65  0.14%   

Insider

MD FASN is Pres CEO of Vertex Pharmaceuticals Incorporated
Age 50
Phone617 341 6100
Webhttps://www.vrtx.com

Vertex Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Vertex Pharmaceuticals Incorporated has accumulated 656.95 M in total debt with debt to equity ratio (D/E) of 12.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has a current ratio of 3.67, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vertex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Paul ManskyBenchmark Electronics
N/A
Christian WittLPKF Laser Electronics
52
JaeYong LeeSamsung Electronics Co
55
Kyehyun KyungSamsung Electronics Co
60
Bret TaylorSalesforce
43
JongHee HanSamsung Electronics Co
61
TaeMoon RohSamsung Electronics Co
55
Rhonda TurnerBenchmark Electronics
50
Dave ClarkBenchmark Electronics
N/A
Scott HicarBenchmark Electronics
56
Marc BenioffSalesforce
58
Ralph SchoiererNucletron Electronic Aktiengese
N/A
Jrgen BergedieckLPKF Laser Electronics
N/A
SangKyun KimSamsung Electronics Co
N/A
Sarah FranklinSalesforce
N/A
Michael BusemanBenchmark Electronics
62
Brent HyderSalesforce
58
Srinivas TallapragadaSalesforce
53
Roop LakkarajuBenchmark Electronics
52
Jeffrey BenckBenchmark Electronics
58
David SchmaierSalesforce
N/A
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people. Vertex Pharmaceuticals Incorporated (VX1) is traded on Frankfurt Exchange in Germany and employs 4,800 people.

Management Performance

Return On Equity0.28
Return On Asset0.17

Vertex Pharmaceuticals Leadership Team

Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffrey MD, Ex Chairman
Ourania Tatsis, Ex Officer
MD FASN, Pres CEO
Susie Lisa, VP Relations
Stuart BSc, Ex COO
Mike Tirozzi, SVP Officer
Damian Esq, Chief VP
Charles Wagner, Ex CFO
Kristen Ambrose, Tax, Accounting

Vertex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.28
Return On Asset0.17
Profit Margin0.37 %
Operating Margin0.49 %
Current Valuation67.44 B
Shares Outstanding257.09 M
Shares Owned By Insiders0.21 %
Shares Owned By Institutions96.26 %
Price To Earning18.50 X
Price To Book6.23 X

Currently Active Assets on Macroaxis

VVisa Class A
SSentinelOne
GMGeneral Motors
MSFTMicrosoft
FFord Motor

Other Information on Investing in Vertex Stock

Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY